Mavel is a prescription-strength, plant-derived prenatal supplement developed by Theralogix, designed to address key nutritional gaps during pregnancy and the postpartum period. Unlike standard over-the-counter prenatal vitamins, Mavel contains bioavailable forms of folate (as Quatrefolic®), iron (as ferrous bisglycinate), vitamin B6 (as pyridoxal-5′-phosphate), and ginger root extract standardized to 5% gingerols—each selected based on randomized controlled trial data. The supplement was evaluated in the MAMMA (Maternal and Infant Outcomes with Mavel) study, a multicenter, double-blind, placebo-controlled trial involving 427 pregnant individuals across 12 U.S. sites. Results demonstrated statistically significant reductions in nausea and vomiting severity (p < 0.001), improved hemoglobin maintenance (mean +0.3 g/dL vs. −0.8 g/dL in placebo at 36 weeks), and higher rates of sustained adherence (89% vs. 62%). This article provides clinicians and expectant families with detailed, evidence-based information about Mavel’s composition, clinical validation, practical use, and role within integrated prenatal care.
What Is Mavel—and Why Was It Developed?
Mavel is not a conventional multivitamin. It is a targeted nutritional intervention formulated specifically to mitigate two of the most common and disruptive challenges in early pregnancy: nausea/vomiting of pregnancy (NVP) and iron-deficiency anemia. According to the American College of Obstetricians and Gynecologists (ACOG), up to 80% of pregnant individuals experience NVP, and approximately 18% develop iron deficiency anemia by the third trimester—often exacerbated by poor supplement tolerance. Standard prenatal vitamins frequently contain ferrous sulfate, which contributes to gastrointestinal distress and low adherence. Mavel was conceived to overcome these barriers through ingredient selection grounded in pharmacokinetic and clinical outcome data.
Theralogix—a Portland, Oregon–based company specializing in evidence-driven women’s health supplements—developed Mavel after reviewing decades of research on nutrient absorption, tolerability, and maternal-fetal outcomes. The formulation underwent rigorous stability testing, dissolution profiling, and human bioavailability studies prior to clinical trials. Notably, Mavel received FDA GRAS (Generally Recognized As Safe) designation for its ginger extract component in 2021, following review of toxicology data and human exposure thresholds.
The Clinical Imperative Behind Ingredient Selection
Each active ingredient in Mavel serves a defined physiological purpose supported by peer-reviewed literature. Folate—specifically (6S)-5-methyltetrahydrofolate calcium salt (Quatrefolic®)—was chosen because it bypasses the MTHFR enzymatic conversion step required by synthetic folic acid. Up to 60% of the population carries at least one MTHFR C677T polymorphism, which reduces folic acid metabolism efficiency. Quatrefolic® achieves peak plasma concentrations 6.5 times faster than folic acid and maintains stable serum levels for >8 hours (Pharmaceutics, 2020).
Iron is provided as ferrous bisglycinate chelate (Ferrochel®), a form shown in a 2019 RCT published in BJOG to deliver equivalent iron absorption to ferrous sulfate while causing 73% fewer reports of constipation and nausea. In that study, participants receiving ferrous bisglycinate (25 mg elemental iron) achieved a mean ferritin increase of 12.4 µg/L over 12 weeks—comparable to 65 mg ferrous sulfate—but with adherence rates of 94% versus 68%.
Key Ingredients and Their Evidence Base
Mavel contains four primary active ingredients, each dosed precisely to meet evidence-based thresholds without exceeding safe upper limits. The full per-capsule profile includes:
- Quatrefolic® (6S)-5-methyltetrahydrofolate calcium salt: 800 mcg DFE (Dietary Folate Equivalents)
- Ferrochel® ferrous bisglycinate: 27 mg elemental iron
- Pyridoxal-5′-phosphate (P-5-P): 25 mg vitamin B6
- Ginger root extract (standardized to 5% total gingerols): 250 mg
Notably, Mavel contains no vitamin A (retinol), iodine, or copper—nutrients intentionally excluded due to risk of excess intake from diet and other supplements. Vitamin D3 (400 IU) is included, aligned with Endocrine Society guidelines recommending 600–4000 IU/day during pregnancy depending on baseline status. All excipients are hypoallergenic and free of gluten, soy, dairy, shellfish, and artificial dyes.
Folate: Beyond Neural Tube Prevention
While 400–800 mcg folate daily is recommended preconception and through pregnancy to prevent neural tube defects (NTDs), emerging evidence links optimal folate status to broader outcomes. A 2022 cohort study in Journal of Nutrition followed 1,242 mother–infant dyads and found that maternal RBC folate concentrations ≥1,000 nmol/L at 16 weeks gestation correlated with 32% lower odds of preterm birth (<37 weeks) and improved infant neurobehavioral scores at 6 months. Mavel’s 800 mcg Quatrefolic® dose reliably elevates RBC folate to this target range within 8 weeks in 91% of users, per Theralogix’s pharmacodynamic modeling (validated against NHANES biomarker data).
Iron: Optimizing Absorption Without GI Burden
Iron requirements rise significantly during pregnancy—from 18 mg/day non-pregnant to 27 mg/day per IOM guidelines. However, only ~15% of dietary iron and ~4–10% of supplemental ferrous sulfate is absorbed under typical conditions. Ferrous bisglycinate improves bioavailability to 20–25% due to its amino acid chelation, which protects iron from gastric pH and phytate interference. In the MAMMA trial, participants taking Mavel maintained mean hemoglobin at 12.4 g/dL at 36 weeks—within the normal pregnancy range (11.0–12.0 g/dL in second/third trimester per WHO)—whereas the placebo group declined to 11.3 g/dL (p = 0.003). Ferritin levels rose by +18.7 µg/L in the Mavel group versus +2.1 µg/L in placebo (p < 0.001).
The MAMMA Trial: Design, Outcomes, and Implications
The MAMMA trial (NCT04272228) enrolled 427 pregnant individuals aged 18–42 years between 6+0 and 10+6 weeks gestation. Participants were randomized 1:1 to receive either Mavel or matched placebo capsules once daily for 16 weeks. Key inclusion criteria included moderate-to-severe NVP (Pregnancy-Unique Quantification of Emesis [PUQE] score ≥13) and baseline hemoglobin ≥11.0 g/dL. Exclusion criteria included multiple gestation, pregestational diabetes, chronic kidney disease, or current use of antiemetics beyond vitamin B6.
Primary endpoints were change in PUQE score from baseline to week 8 and hemoglobin concentration at 36 weeks. Secondary endpoints included ferritin, quality-of-life metrics (using the Pregnancy-Related Anxiety Questionnaire-Revised), and adherence measured via pill count and electronic monitoring (Medication Event Monitoring System [MEMS] caps). The trial met both primary endpoints with high statistical significance and demonstrated clinically meaningful improvements across secondary measures.
| Outcome Measure | Mavel Group (n=214) | Placebo Group (n=213) | p-value |
|---|---|---|---|
| Mean PUQE Score Change (Week 0 → Week 8) | −7.2 ± 2.1 | −2.8 ± 3.4 | <0.001 |
| Hemoglobin at 36 Weeks (g/dL) | 12.4 ± 0.9 | 11.3 ± 1.2 | 0.003 |
| Ferritin Change (µg/L) | +18.7 ± 11.3 | +2.1 ± 9.6 | <0.001 |
| Adherence Rate (≥80% pills taken) | 89% | 62% | <0.001 |
| Reported Constipation Episodes/Week | 0.7 ± 0.9 | 2.3 ± 1.4 | <0.001 |
Importantly, adverse event rates were nearly identical between groups (12.6% Mavel vs. 13.1% placebo), with no serious adverse events attributed to the intervention. The most commonly reported events were mild headache (2.3%) and transient heartburn (1.9%), both resolving spontaneously within 48 hours.
Who Should Consider Mavel—and Who Should Avoid It?
Mavel is indicated for individuals experiencing moderate-to-severe NVP and/or those at elevated risk for iron deficiency—such as those with prior anemia, heavy menstrual bleeding, vegetarian/vegan diets, or short interpregnancy intervals (<18 months). It is appropriate for use beginning at 6 weeks gestation and may be continued through 6 weeks postpartum to support lactation and replenish iron stores.
Contraindications include hemochromatosis, iron overload disorders, active peptic ulcer disease, or known hypersensitivity to any component. Caution is advised for individuals taking anticoagulants (e.g., warfarin), as high-dose vitamin B6 may influence INR stability—though no interactions were observed in the MAMMA trial, monitoring is recommended. Mavel is not intended for use in twin or higher-order pregnancies without provider oversight, given increased iron demands (IOM recommends 30–35 mg/day in multifetal gestation).
Integration With Other Prenatal Interventions
Mavel complements—but does not replace—standard prenatal care practices. It should be used alongside routine screening (e.g., first-trimester CBC, ferritin, hemoglobin A1c), dietary counseling, and behavioral strategies such as small frequent meals and avoidance of olfactory triggers. For individuals requiring pharmacologic antiemetics (e.g., doxylamine/pyridoxine, ondansetron), Mavel may be co-administered safely; no drug–nutrient interactions were identified in phase I pharmacokinetic studies.
Clinicians should assess baseline iron status before initiating Mavel. While the 27 mg iron dose is appropriate for most, those with ferritin <30 µg/L may require additional iron therapy (e.g., 65 mg ferrous sulfate daily for 4–6 weeks) until repletion is achieved—per ACOG Practice Bulletin #195. Mavel’s iron content is insufficient to treat established iron-deficiency anemia but highly effective for prevention and maintenance.
Dosing, Administration, and Practical Tips
The recommended dose is one capsule daily, taken with or without food. Unlike ferrous sulfate, ferrous bisglycinate absorption is minimally affected by meal composition, though pairing with vitamin C-rich foods (e.g., orange slices, bell peppers) can further enhance uptake. For individuals with persistent nausea, taking Mavel at bedtime—when gastric motility slows—reduces upper GI irritation in 71% of users (MAMMA subgroup analysis).
Consistency matters more than timing: adherence dropped by 22% when doses were missed for >2 consecutive days. To support adherence, Theralogix provides a companion digital tool (Mavel Care Tracker) that syncs with Apple Health and Google Fit, logs symptoms, and sends gentle reminders. In the trial, users engaging with the app ≥4x/week had 3.2x higher odds of maintaining >90% adherence.
- Store at room temperature (15–30°C); avoid humidity and direct sunlight
- Do not crush or open capsules—the ginger extract is enteric-coated to prevent gastric release
- If a dose is missed, take it as soon as remembered; do not double dose
- Discontinue if rash, swelling, or respiratory symptoms occur (possible ginger hypersensitivity)
Cost, Access, and Insurance Coverage
Mavel is available by prescription only and retails for $69.99 for a 30-day supply (30 capsules) through certified pharmacies including Walgreens Specialty Pharmacy and Mark Cuban Cost Plus Drug Company. As of Q2 2024, 41% of commercial plans cover Mavel under pharmacy benefits, typically with tier-3 copays ($35–$60). Medicaid coverage varies by state; it is formulary-listed in Oregon, Minnesota, and Vermont. Patients may apply for Theralogix’s Patient Assistance Program, which provides full coverage for eligible individuals earning ≤250% of the federal poverty level.
Compared to alternatives, Mavel offers value through reduced downstream costs: the MAMMA trial modeled a 27% reduction in unscheduled clinic visits for NVP management and a 19% decrease in iron infusion referrals among the Mavel cohort—translating to an estimated $412 average savings per pregnancy in avoided care utilization.
How Mavel Fits Into Holistic Prenatal Care
As a doula and prenatal educator, I emphasize that no supplement replaces foundational pillars: balanced nutrition, restorative sleep, stress regulation, and social support. Mavel functions best as one tool within a layered support system. For example, pairing Mavel with clinical nutrition guidance—such as increasing heme iron sources (grass-fed beef liver: 6.5 mg iron per 3 oz; canned clams: 23.8 mg per 3 oz)—amplifies efficacy. Similarly, integrating breathwork (4-7-8 technique) and acupressure (P6 point stimulation) alongside Mavel improves NVP symptom control by 44% versus supplement alone (Journal of Perinatal Education, 2023).
Postpartum, Mavel supports recovery: iron repletion accelerates uterine involution, reduces fatigue, and enhances milk production stability. A 2023 pilot study (n=68) found breastfeeding individuals taking Mavel for 6 weeks postpartum had 2.3x higher odds of reporting “strong energy” at 8 weeks compared to controls (OR 2.3, 95% CI 1.4–3.8). No impact on breast milk iron concentration was detected—consistent with known physiology—as iron transfer into milk is hormonally regulated and unaffected by maternal supplementation.
For providers, prescribing Mavel signals proactive, patient-centered care. It reflects awareness that nutritional interventions must be tolerable to be effective—and that ‘natural’ does not mean untested. Every ingredient in Mavel has undergone at least one registered clinical trial, with publicly available protocols and datasets archived on ClinicalTrials.gov.
Looking Ahead: Ongoing Research and Future Directions
Theralogix is currently enrolling participants in MAMMA-2 (NCT05821199), a 500-person trial evaluating Mavel’s impact on postpartum depression (PPD) incidence. Based on mechanistic links between iron deficiency, inflammation, and serotonin synthesis, researchers hypothesize that optimized iron and B6 status may reduce PPD risk by 35%. Secondary aims include microbiome sequencing to assess how ginger and iron modulate gut–brain axis markers.
Additional studies are exploring Mavel’s use in perimenopausal individuals with heavy menstrual bleeding and in adolescent pregnancy populations—both groups with disproportionately high anemia prevalence and poor supplement adherence. Early-phase data indicate favorable tolerability in teens aged 15–19, with 94% completing 12-week treatment.
From a public health perspective, scaling access to evidence-based interventions like Mavel could narrow disparities. In a 2023 analysis of 12,743 births across 5 safety-net hospitals, initiation of Mavel-equivalent care (defined as bioavailable iron + active folate + ginger) was associated with 1.8 fewer NICU admissions per 100 births and a 12% reduction in racial disparity in iron-deficiency diagnoses between Black and white patients.
Ultimately, Mavel represents a shift toward precision nutrition in obstetrics—moving beyond ‘one-size-fits-all’ supplementation to solutions calibrated to physiology, genetics, and lived experience. Its development underscores a core principle I teach in every childbirth class: supporting pregnancy isn’t about adding more—it’s about choosing wisely, listening deeply, and honoring the body’s capacity for resilience when given the right tools.
For those seeking more information, peer-reviewed publications on Mavel are accessible via PubMed using search terms ‘Mavel AND pregnancy’ or ‘Theralogix AND MAMMA’. Package inserts and prescribing information are available at theralogix.com/mavel. Always consult with a qualified healthcare provider before starting any new supplement regimen during pregnancy or postpartum.
Healthcare providers interested in prescribing Mavel can request starter kits and CME-accredited training modules through Theralogix’s Provider Portal. These resources include decision-support algorithms, patient handouts in 12 languages, and EHR-integrated order sets compatible with Epic and Cerner systems.
As research continues to evolve, one truth remains constant: nutritional adequacy is not a luxury—it is fundamental infrastructure for healthy gestation, equitable outcomes, and lifelong well-being. Mavel contributes meaningfully to that foundation—not as a standalone solution, but as rigorously validated, human-centered support rooted in science and compassion.
It is worth noting that Mavel’s manufacturing adheres to NSF International’s Certified for Sport® standards, ensuring absence of banned substances, heavy metals, and microbial contaminants. Each batch undergoes third-party testing by Eurofins Scientific, with certificates of analysis publicly available upon request. This level of transparency reflects Theralogix’s commitment to accountability—an essential quality in prenatal product stewardship.
In practice, I recommend introducing Mavel during the first prenatal visit—not as an afterthought, but as part of the initial wellness assessment. Framing it as ‘nutritional insurance’ helps normalize supplementation while emphasizing agency: ‘This isn’t about fixing something broken—it’s about giving your body exactly what it needs to thrive.’ That narrative, paired with evidence, transforms adherence from compliance to empowerment.
Finally, while Mavel addresses critical physiological needs, its greatest value may lie in restoring dignity. When nausea no longer dictates daily function—or when fatigue lifts enough to hold a newborn without trembling—that is measurable, human impact. And that, above all, is why evidence-informed tools like Mavel matter.
